H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

Go back to H.C. Wainwright Reiterates Buy Rating on Annexon Biosciences (ANNX)

Annexon, Inc. (ANNX) Reports In-Line Q2 EPS

August 12, 2024 8:40 AM EDT

Annexon, Inc. (NASDAQ: ANNX) reported Q2 EPS of ($0.23), in-line with the analyst estimate of ($0.23). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Annexon, Inc. (ANNX) click here.

... More